# psoriasis - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 18323
- Completion tokens: 6782
- Reasoning tokens: 0
- Total tokens: 25105
- API requests reported: 2
- Elapsed seconds: 217.127
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: Anthropic

---
# Multidimensional Interpretation of Psoriatic Lesional Skin Transcriptomics

## 1. Overall Biological Interpretation

The transcriptomic signature of psoriatic lesional skin reveals a profound epithelial hyperactivation state dominated by innate immune signaling, barrier dysfunction, and keratinocyte hyperproliferation. With 90% of differentially expressed genes upregulated, the data reflects the characteristic inflammatory amplification loop of psoriasis rather than a balanced immune response.

The molecular landscape is organized around three interdependent axes: (1) IL-17/IL-36 cytokine amplification driving sustained inflammation, (2) antimicrobial peptide overproduction and abnormal cornification indicating barrier compromise, and (3) metabolic reprogramming in keratinocytes supporting hyperproliferative epidermis. The magnitude of changes—with multiple genes showing log2FC >7—combined with highly significant FDR values, indicates these are not subtle perturbations but core disease-defining programs.

Notably, the near-absence of downregulated genes (only 10/100) suggests psoriasis lesions are characterized more by pathological gain-of-function programs than loss of homeostatic mechanisms. The few downregulated genes include BTC (betacellulin, log2FC=-4.3), potentially reflecting disrupted growth factor signaling that normally maintains barrier integrity.

## 2. Core Biological Programs

### **Program 1: IL-17/IL-36 Cytokine Amplification Network**

**Direction:** Strongly upregulated  
**Major supporting genes:** IL36A (log2FC=11.37), IL36G (log2FC=5.68), IL19 (log2FC=7.58), IL20 (log2FC=5.67), IL36RN (present in network), TNIP3 (log2FC=7.28)

**Pathway:** KEGG IL-17 signaling pathway; GO Response to Lipopolysaccharide (GO:0032496); Reactome Cytokine Signaling  

**Biological rationale:**  
IL-36 cytokines (IL-36α and IL-36γ) are among the most dramatically upregulated genes in this dataset and represent master inflammatory amplifiers in psoriatic skin. IL-36 signals through IL-1RAP (confirmed network hub with 3 selected gene interactions), creating a feed-forward loop with IL-17 signaling that sustains keratinocyte activation. IL-19 and IL-20, both IL-20 subfamily members, contribute to epidermal hyperplasia and are specifically induced in psoriatic lesions. TNIP3 (TNFAIP3-interacting protein 3) is an NF-κB pathway modulator whose upregulation reflects chronic inflammatory signaling. The network evidence shows IL1RAP as a hub connecting IL36A, IL36G, and IL36RN, confirming the coordinated activation of this cytokine axis.

**Evidence strength and limitations:**  
**Strength: Very high.** Multiple independent cytokine family members are concordantly and dramatically upregulated (log2FC 5.7–11.4, all FDR <1e-80). IL-36 upregulation in psoriasis is extensively replicated across independent cohorts in the literature. Pathway enrichment (IL-17 signaling, cytokine-cytokine receptor interaction) and network analysis (IL1RAP hub) provide convergent support.

**Limitations:** The dataset does not include actual IL-17 family members (IL-17A/F), which are primarily produced by infiltrating immune cells rather than keratinocytes, so we are observing downstream keratinocyte responses rather than the complete inflammatory network. Causal directionality—whether IL-36 amplifies IL-17 responses or vice versa—cannot be determined from cross-sectional expression data.

---

### **Program 2: Antimicrobial Peptide Hyperproduction and Innate Immune Defense**

**Direction:** Strongly upregulated  
**Major supporting genes:** DEFB4A (log2FC=11.18), DEFB4B (log2FC=11.03), DEFB103A (log2FC=5.76), DEFB103B (log2FC=5.75), S100A12 (log2FC=8.33), PI3 (log2FC=9.24), TCN1 (log2FC=8.04)

**Pathway:** GO Antimicrobial Humoral Response (GO:0019730); KEGG Staphylococcus aureus infection

**Biological rationale:**  
Beta-defensins (DEFB4A/B, DEFB103A/B) and S100 family antimicrobial proteins represent the epithelial innate immune arsenal. Their dramatic upregulation (log2FC 5.8–11.2) reflects both a response to barrier breach and active keratinocyte participation in immune defense. DEFB4A/B (β-defensin-2) are directly induced by IL-17 and IL-36, linking this program mechanistically to Program 1. PI3 (elafin/SKALP) is a serine protease inhibitor with antimicrobial properties, highly specific to psoriasis. CCR6 emerges as a network hub connecting three defensins, consistent with its role as a chemokine receptor that guides defensin-expressing cells. The magnitude of beta-defensin upregulation (>1000-fold at linear scale) exceeds typical inflammatory responses, suggesting feed-forward amplification.

**Evidence strength and limitations:**  
**Strength: Very high.** The concerted upregulation of multiple antimicrobial peptide families (defensins, S100 proteins, protease inhibitors) with extreme fold-changes and significance (FDR <1e-68 for all major defensins) provides robust evidence. Network analysis confirms functional clustering (CCR6 hub). Antimicrobial peptide overproduction is a replicated hallmark of psoriasis pathogenesis and correlates with disease severity in published cohorts.

**Limitations:** Antimicrobial peptides have immunomodulatory functions beyond microbial defense—LL-37 (not present in top genes) activates plasmacytoid dendritic cells, and S100 proteins can amplify inflammation through TLR4. The dataset does not distinguish protective antimicrobial activity from pathological autoinflammation. Whether microbiome alterations drive or result from this response cannot be determined.

---

### **Program 3: Abnormal Cornification and Barrier Dysfunction**

**Direction:** Upregulated  
**Major supporting genes:** SPRR2A (log2FC=7.31), SPRR2B (log2FC=6.38), SPRR2D (log2FC=5.92), SPRR2E (log2FC=3.99), SPRR3 (log2FC=7.18), LCE3A, LCE3D, KRT6A (log2FC=4.30), GJB2 (log2FC=4.42), GJB6 (log2FC=3.02)

**Pathway:** Reactome Formation of the Cornified Envelope (R-HSA-6809371); GO Epidermis Development (GO:0008544)

**Biological rationale:**  
Small proline-rich repeat proteins (SPRR2A/B/D/E, SPRR3) and late cornified envelope proteins (LCE3A/D) are structural components of the cornified envelope that are abnormally expressed in psoriatic hyperproliferative epidermis. Network analysis identifies SPRR1B (not in input but detected as hub) connecting 8 selected genes including SPRR2A/B/D/E and KRT6A, confirming coordinated expression of this cornification module. KRT6A (keratin 6A) is a stress-induced keratin typical of activated keratinocytes. Gap junction proteins GJB2 (connexin 26) and GJB6 (connexin 30) are upregulated, reflecting altered keratinocyte communication. The Reactome pathway "Formation of the cornified envelope" captures 12 genes from the selected set, demonstrating pathway-level dysregulation rather than isolated gene changes.

**Evidence strength and limitations:**  
**Strength: High.** Multiple cornification proteins are upregulated with strong statistical support (FDR <1e-77 for SPRR2 family members). Network clustering (SPRR1B hub with 8 connections, SPRR2B hub with 6 connections) confirms functional module coherence. This program is biologically distinct from immune activation (Program 1–2) and represents a keratinocyte-intrinsic differentiation defect characteristic of psoriasis.

**Limitations:** Upregulation of cornification genes could be compensatory (attempting barrier repair) or pathological (producing abnormal cornified envelope). The balance between hyperproliferation and differentiation cannot be resolved from expression data alone. LCE3 deletion variants are genetically associated with psoriasis susceptibility, but paradoxically LCE3 genes are upregulated in lesions—expression levels do not directly correspond to genetic risk architecture.

---

### **Program 4: Lipid Metabolism Reprogramming**

**Direction:** Upregulated  
**Major supporting genes:** FABP5 (log2FC=3.65), AKR1B10 (log2FC=6.27), AKR1B15 (log2FC=5.23), PLA2G4D (log2FC=4.62), PLA2G4E, ABCG4 (log2FC=4.75)

**Pathway:** GO Lipid Metabolic Process; Reactome Metabolism of Lipids

**Biological rationale:**  
FABP5 (fatty acid binding protein 5) is a cytoplasmic lipid chaperone that delivers ligands to PPARβ/δ, promoting keratinocyte proliferation and inflammation. Its upregulation links lipid metabolism to hyperproliferation. AKR1B10 and AKR1B15 (aldo-keto reductases) metabolize retinaldehyde and lipid aldehydes, with AKR1B10 specifically implicated in hyperproliferative diseases. PLA2G4D (phospholipase A2 group IVD) liberates arachidonic acid for eicosanoid synthesis, connecting to inflammatory lipid mediators. GNAS emerges as a network hub connecting PLA2G4D/E with HRH2, suggesting coordinated regulation of lipid signaling. ABCG4 is a sterol transporter. Together, these genes indicate reprogramming of keratinocyte lipid metabolism to support proliferation and inflammatory mediator production.

**Evidence strength and limitations:**  
**Strength: Moderate to High.** Multiple independent lipid metabolism genes are upregulated with robust statistics (FDR <1e-72 for all listed genes). FABP5-PPARβ/δ axis is mechanistically linked to psoriasis pathogenesis in mouse models. Network analysis (GNAS hub) supports functional connectivity. Lipid metabolism is less investigated than immune pathways in psoriasis but increasingly recognized as contributing to disease.

**Limitations:** The specific consequences of each metabolic enzyme upregulation are not fully characterized. Some changes (e.g., ABCG4) may be compensatory lipid efflux mechanisms rather than pathogenic drivers. The dataset does not include lipid mediator measurements, so we infer functional consequences from enzyme expression. The connection between lipid reprogramming and clinical features (e.g., scale formation, inflammation) requires mechanistic validation.

---

### **Program 5: Extracellular Matrix Remodeling and Protease Activity**

**Direction:** Mixed upregulation; one key growth factor downregulated  
**Major supporting genes:** KLK13 (log2FC=4.05), SERPINB3 (log2FC=6.74), SERPINB4, SERPINB13, HPSE (heparanase, log2FC=2.92), TMPRSS11D (log2FC=7.75), BTC (betacellulin, log2FC=-4.30, downregulated)

**Pathway:** GO Extracellular Region (GO:0005576); Reactome ECM Organization

**Biological rationale:**  
Kallikrein-related peptidase 13 (KLK13) and transmembrane serine protease 11D (TMPRSS11D) are upregulated, indicating increased proteolytic activity in lesional skin. SERPINB3, SERPINB4, and SERPINB13 (serine protease inhibitors) are counter-regulatory but also inflammatory mediators themselves—SERPINB3/4 are extracellular inhibitors that can be released by damaged keratinocytes. Network analysis confirms CTSG (cathepsin G, not in input) as a hub connecting SERPINB13, SERPINB3, and SERPINB4, indicating coordinated protease-inhibitor regulation. Heparanase (HPSE) degrades heparan sulfate in basement membranes, facilitating inflammatory cell infiltration. Notably, BTC (betacellulin), an EGFR ligand that supports epithelial homeostasis, is one of the few strongly downregulated genes (log2FC=-4.30, FDR=1.8e-73), suggesting loss of normal growth factor signaling alongside proteolytic hyperactivity.

**Evidence strength and limitations:**  
**Strength: Moderate.** Multiple proteases and their inhibitors are upregulated with strong statistical significance, and network analysis (CTSG hub, S100A7 hub connecting SERPINB3/4) confirms functional relationships. The downregulation of BTC provides a mechanistically coherent counterpoint—loss of homeostatic growth factor signaling alongside protease activation. GO term enrichment for extracellular region (19 genes) supports secreted protein dysregulation.

**Limitations:** Protease/inhibitor systems are complex feedback networks where upregulation of inhibitors can indicate either protective responses or chronic activation states. The functional net effect (proteolysis vs. inhibition) cannot be determined from mRNA levels alone. TMPRSS11D has limited functional characterization in psoriasis. The mechanistic link between BTC downregulation and protease upregulation is inferred but not directly demonstrated by these data. This program is less extensively replicated in the psoriasis literature compared to Programs 1–3.

---

## Summary

The five programs collectively describe psoriasis as a disease of epithelial-immune amplification rather than a simple inflammatory disorder. The IL-17/IL-36 axis (Program 1) drives antimicrobial peptide production (Program 2) and sustains keratinocyte activation, while intrinsic keratinocyte defects in cornification (Program 3) and lipid metabolism (Program 4) create a self-perpetuating hyperproliferative state. Protease dysregulation and growth factor loss (Program 5) contribute to barrier dysfunction and tissue remodeling.

The extreme magnitude and statistical significance of these changes—particularly for cytokines, defensins, and cornification proteins—indicate these are core disease mechanisms rather than peripheral responses. The near-complete absence of downregulated genes suggests that therapeutic strategies may need to actively suppress pathological gain-of-function programs rather than restore lost functions.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=34, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
